Variation in Placebo Effect Sizes in Clinical Trials of Oral Interventions for Management of the Behavioral and Psychological Symptoms of Dementia (BPSD): A Systematic Review and Meta-Analysis

American Journal of Geriatric Psychiatry

Volumn 25, Issue 9, 2017, Pages 994-1008

  Hyde, Anna J ^a   May, Brian H ^a   Xue, Charlie Changli ^a   Zhang, Anthony L ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Alzheimer disease; Dementia; meta analysis; neuropsychiatric; placebo; systematic review

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; DEMENTIA; HUMAN; MENTAL DISEASE; META ANALYSIS; NEUROPSYCHIATRIC INVENTORY; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; PATHOPHYSIOLOGY; PROBLEM BEHAVIOR; PSYCHOLOGY; SAMPLE SIZE; STATISTICS AND NUMERICAL DATA;

DEMENTIA; HUMANS; PLACEBO EFFECT; PROBLEM BEHAVIOR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE;

EID: 85016733010     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2017.02.022     Document Type: Review

References (79)

1. Gotzsche, P.C., Is there logic in the placebo?. Lancet 344 (1994), 925–926.
2. Shorter, E., A brief history of placebos and clinical trials in psychiatry. Can J Psychiatry 56 (2011), 193–197.
3. McQueen, D., Cohen, S., St John-Smith, P., et al. Rethinking placebo in psychiatry: the range of placebo effects. Adv Psychiatry Treat, 19, 2013, 162.
4. Dollfus, S., Lecardeur, L., Morello, R., et al. Placebo response in repetitive transcranial magnetic stimulation trials of treatment of auditory hallucinations in schizophrenia: a meta-analysis. Schizophr Bull 42 (2016), 301–308.
5. McDonald, C.J., Mazzuca, S.A., McCabe, G.P. Jr, How much of the placebo “effect” is really statistical regression?. Stat Med 2 (1983), 417–427.
6. Kienle, G.S., Kiene, H., The powerful placebo effect: fact or fiction?. J Clin Epidemiol 50 (1997), 1311–1318.
7. Fava, M., Evins, A.E., Dorer, D.J., et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72 (2003), 115–127.
8. Kleist, P., Quatre effets, phenomenes et paradoxes de la medecine. Forum Med Suisse 6 (2006), 1023–1027.
9. Hrobjartsson, A., What are the main methodological problems in the estimation of placebo effects?. J Clin Epidemiol 55 (2002), 430–435.
10. Kaptchuk, T.J., Miller, F.G., Placebo effects in medicine. N Engl J Med 373 (2015), 8–9.
11. Weimer, K., Colloca, L., Enck, P., Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry 2 (2015), 246–257.
12. Miller, F.G., Kaptchuk, T.J., The power of context: reconceptualizing the placebo effect. J R Soc Med 101 (2008), 222–225.
13. Walsh, B.T., Seidman, S.N., Sysko, R., et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287 (2002), 1840–1847.
14. Rief, W., Nestoriuc, Y., Weiss, S., et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 118 (2009), 1–8.
15. Kemp, A.S., Schooler, N.R., Kalali, A.H., et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?. Schizophr Bull 36 (2010), 504–509.
16. Alphs, L., Benedetti, F., Fleischhacker, W.W., et al. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?. Int J Neuropsychopharmacol 15 (2012), 1003–1014.
17. Klein, J.B., Jacobs, R.H., Reinecke, M.A., Cognitive-behavioral therapy for adolescent depression: a meta-analytic investigation of changes in effect-size estimates. J Am Acad Child Adolesc Psychiatry 46 (2007), 1403–1413.
18. Davey, C.G., Chanen, A.M., The unfulfilled promise of antidepressant medications. Med J Aust 204 (2016), 348–350.
19. Jones, R.W., Schwam, E., Wilkinson, D., et al. Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer Dis Assoc Disord 23 (2009), 357–364.
20. Bakchine, S., Loft, H., Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 13 (2008), 97–107.
21. Herrmann, N., Gauthier, S., Boneva, N., et al. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. Int Psychogeriatr 25 (2013), 919–927.
22. Nikolova, G., Yancheva, S., Raychev, I., et al. Ginkgo biloba extract in dementia: a 22-week randomised, placebo-controlled, double-blind trial. Bulg Neurol 14 (2013), 139–143.
23. Rosenberg, P.B., Drye, L.T., Porsteinsson, A.P., et al. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr 27 (2015), 2059–2067.
24. Finkel, S.I., Costa e Silva, J., Cohen, G., et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 8:suppl 3 (1996), 497–500.
25. Donaldson, C., Tarrier, N., Burns, A., Determinants of carer stress in Alzheimer's disease. Int J Geriatr Psychiatry 13 (1998), 248–256.
26. Lyketsos, C.G., Steinberg, M., Tschanz, J.T., et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157 (2000), 708–714.
27. Lopez, O.L., Becker, J.T., Chang, Y.F., et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry 170 (2013), 1051–1058.
28. Guideline Adaption Committee, Clinical Practice Guidelines and Principles of Care for People with Dementia. Sydney, Australia, NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People, 2016.
29. NICE National Institute for Health and Clinical Excellence, A NICE-SCIE Guideline on Supporting People with Dementia and their Carers in Health and Social Care. London, The British Psychological Society, 2007 updated in 2014.
30. de Oliveira, A.M., Radanovic, M., de Mello, P.C., et al. Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review. Biomed Res Int, 2015, 2015, 218980.
31. McClam, T.D., Marano, C.M., Rosenberg, P.B., et al. Interventions for neuropsychiatric symptoms in neurocognitive impairment due to Alzheimer's disease: a review of the literature. Harv Rev Psychiatry 23 (2015), 377–393.
32. Antonsdottir, I.M., Smith, J., Keltz, M., et al. Advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother 16 (2015), 1649–1656.
33. Magierski, R., Sobow, T., Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia. Expert Rev Neurother 16 (2016), 375–387.
34. Schneider, L.S., Tariot, P.N., Dagerman, K.S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 (2006), 1525–1538.
35. Maree, R.D., Marcum, Z.A., Saghafi, E., et al. A systematic review of opioid and benzodiazepine misuse in older adults. Am J Geriatr Psychiatry 24 (2016), 949–963.
36. Maust, D.T., Kim, H.M., Seyfried, L.S., et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 72 (2015), 438–445.
37. Looi, J.C., Macfarlane, S., Psychotropic drug use in aged care facilities: a reflection of a systemic problem?. Med J Aust 200 (2014), 13–14.
38. Naples, J.G., Kotlarczyk, M.P., Perera, S., et al. Non-tricyclic and non-selective serotonin reuptake inhibitor antidepressants and recurrent falls in frail older women. Am J Geriatr Psychiatry 12 (2016), 1221–1227.
39. Ensrud, K.E., Blackwell, T.L., Mangione, C.M., et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 50 (2002), 1629–1637.
40. Cummings, J.L., Mega, M., Gray, K., et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994), 2308–2314.
41. Cummings, J.L., The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 48 (1997), S10–S16.
42. Mega, M.S., Masterman, D.M., O'Connor, S.M., et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56 (1999), 1388–1393.
43. Sinyor, M., Levitt, A.J., Cheung, A.H., et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71 (2010), 270–279.
44. Kaufer, D.I., Cummings, J.L., Ketchel, P., et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12 (2000), 233–239.
45. McKeith, I., Del Ser, T., Spano, P., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356 (2000), 2031–2036.
46. Tariot, P.N., Cummings, J.L., Katz, I.R., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 49 (2001), 1590–1599.
47. Tune, L., Tiseo, P.J., Ieni, J., et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11 (2003), 169–177.
48. Peskind, E.R., Tsuang, D.W., Bonner, L.T., et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord 19 (2005), 23–28.
49. Winblad, B., Kilander, L., Eriksson, S., et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 367 (2006), 1057–1065.
50. Peskind, E.R., Potkin, S.G., Pomara, N., et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14 (2006), 704–715.
51. Chappell, A.S., Gonzales, C., Williams, J., et al. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 68 (2007), 1008–1012.
52. Napryeyenko, O., Borzenko, I., Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 57 (2007), 4–11.
53. Mok, V., Wong, A., Ho, S., et al. Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatry Dis Treat 3 (2007), 943–948.
54. van Dyck, C.H., Tariot, P.N., Meyers, B., et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 21 (2007), 136–143.
55. Howard, R.J., Juszczak, E., Ballard, C.G., et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357 (2007), 1382–1392.
56. de Jong, D., Jansen, R., Hoefnagels, W., et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS ONE, 3, 2008 e1475.
57. Wang, L.Y., Shofer, J.B., Rohde, K., et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 17 (2009), 744–751.
58. Emre, M., Tsolaki, M., Bonuccelli, U., et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9 (2010), 969–977.
59. Vercelletto, M., Boutoleau-Bretonniere, C., Volteau, C., et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis 23 (2011), 749–759.
60. Bi, M., Tong, S., Zhang, Z., et al. Changes in cerebral glucose metabolism in patients with mild-to-moderate Alzheimer's disease: a pilot study with the Chinese herbal medicine fuzhisan. Neurosci Lett 501 (2011), 35–40.
61. Ihl, R., Bachinskaya, N., Korczyn, A.D., et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry 26 (2011), 1186–1194.
62. Herrschaft, H., Nacu, A., Likhachev, S., et al. Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatry Res 46 (2012), 716–723.
63. Fox, C., Crugel, M., Maidment, I., et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS ONE, 7, 2012 e35185.
64. Schwam, E.M., Nicholas, T., Chew, R., et al. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res 11 (2014), 413–421.
65. Tsai, C.H., Huang, H.C., Liu, B.L., et al. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia. Psychiatry Clin Neurosci 68 (2014), 692–700.
66. Gavrilova, S.I., Preuss, U.W., Wong, J.W., et al. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. Int J Geriatr Psychiatry 29 (2014), 1087–1095.
67. van den Elsen, G.A., Ahmed, A.I., Verkes, R.J., et al. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am J Geriatr Psychiatry 23 (2015), 1214–1224.
68. Furukawa, K., Tomita, N., Uematsu, D., et al. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease. Geriatr Gerontol Int 17 (2017), 211–218.
69. Kirsch, I., Deacon, B.J., Huedo-Medina, T.B., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med, 5, 2008, e45.
70. National Institute for Clinical Excellence, Depression: management of depression in primary and secondary care. Clin Practice Guideline, 23, 2004, 670 National Institute for Clinical Excellence.
71. McAllister-Williams, R.H., Do antidepressants work? A commentary on “Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration” by Kirsch et al. Evid Based Ment Health 11 (2008), 66–68.
72. Porsteinsson, A.P., Drye, L.T., Pollock, B.G., et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311 (2014), 682–691.
73. Kaptchuk, T.J., Kelley, J.M., Conboy, L.A., et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336 (2008), 999–1003.
74. Ornstein, K., Gaugler, J.E., The problem with “problem behaviors”: a systematic review of the association between individual patient behavioral and psychological symptoms and caregiver depression and burden within the dementia patient-caregiver dyad. Int Psychogeriatr 24 (2012), 1536–1552.
75. Huis In Het Veld, J., Verkaik, R., van Meijel, B., et al. Self-management by family caregivers to manage changes in the behavior and mood of their relative with dementia: an online focus group study. BMC Geriatr, 16, 2016, 95.
76. Schulz, K.F., Altman, D.G., Moher, D., et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med, 7, 2010, e1000251.
77. Hrobjartsson, A., Gotzsche, P.C., Placebo interventions for all clinical conditions. Cochrane Database Syst Rev(3), 2010 Cd003974.
78. Khan, A., Brown, W.A., Antidepressants versus placebo in major depression: an overview. World Psychiatry 14 (2015), 294–300.
79. Lai, C.K., The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders. Clin Interv Aging 9 (2014), 1051–1061.